Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
46.91
Price to sales ratio
3.96
Dividends per share
0.28
Dividend yield %
0.29

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
565
GH
Guardant Health, Inc. - Common Stock
168.52 USD-1.40%+0.32%+17.34%+132.25%22.61 B USD
662
MEDP
Medpace Holdings, Inc. - Common Stock
611.57 USD-1.21%-0.42%+7.13%+0.82%17.07 B USD
744
CRL
Charles River Laboratories International, Inc. Common Stock
296.36 USD+0.45%+1.70%+23.60%+50.55%14.15 B USD
786
ICLR
ICON plc - Ordinary Shares
169.72 USD+0.47%-1.91%-5.71%-3.27%13.00 B USD

Frequently asked questions about Revvity, Inc.

What is the Revvity, Inc. stock price today?

The current price of Revvity, Inc. (RVTY) is 129.67. Over the past 24 hours, the stock has changed by +2.61%. Follow the RVTY chart for real-time price dynamics.

What is the stock ticker of Revvity, Inc.?

Revvity, Inc. trades under the ticker RVTY. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Revvity, Inc. stock going up?

RVTY has changed by +4.57% over the last week, +16.40% over the last month, and +36.70% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Revvity, Inc.?

Revvity, Inc. currently has a market capitalization of 14.47 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

Does Revvity, Inc. release financial reports?

Yes. You can track Revvity, Inc. financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What were Revvity, Inc. earnings last quarter?

Last quarter, Revvity, Inc. reported earnings of 0.86 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Revvity, Inc. revenue for the last quarter?

Revvity, Inc. reported quarterly revenue of 772.06 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Revvity, Inc. net income for the last quarter?

Revvity, Inc. reported net income of 98.36 M for the last quarter. The previous quarter showed 46.65 M, which means net income changed by +110.85%.

Does Revvity, Inc. pay dividends?

Revvity, Inc. paid a dividend per share of 0.07. The current dividend yield is 0.29%. Dividend data can help income-focused investors evaluate the stock.

Is Revvity, Inc. a good dividend stock?

Revvity, Inc. currently has a dividend yield of 0.29%. Previously, the dividend yield was 0.33%, compared with 0.25% a year earlier. When evaluating dividend stocks, investors should also consider earnings, cash flow, and the sustainability of future dividend payments.

How many employees does Revvity, Inc. have?

As of the latest available data, Revvity, Inc. has 11 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Revvity, Inc. EBITDA?

Revvity, Inc. EBITDA is 229.63 M, and its EBITDA margin is 29.74%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Revvity, Inc. stock?

You can buy Revvity, Inc. (RVTY) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Revvity, Inc. stock?

Investing in Revvity, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the RVTY chart and related analysis on metatrader.com as part of your research.

Revvity, Inc. Common Stock

Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines. In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY.

News